Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Validity of UCSD Performance-Based Skills Assessment in Parkinson’s Disease
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
066
Examine the validity of the UCSD Performance-Based Skills Assessment (UPSA) in Parkinson’s disease (PD) longitudinally.
Reliable assessment of functional independence is necessary for accurate cognitive classification and these measures must be sensitive to changes over time. Our group has previously demonstrated cross-sectional validity of the UPSA for assessment of daily function abilities related to cognition in PD. We now aim to characterize cognitive functional changes longitudinally with UPSA, including determining the predictive validity of baseline cognitive functional status for future cognitive decline in PD.  
46 PD (34 normal cognition (PD-NC), 12 mild cognitive impairment (PD-MCI)) participants completed neuropsychological testing and UPSA at baseline and follow-up (mean duration: 15.5±3.3 months). Cognitive composite scores were calculated by averaging normative Z-scores for 10 neuropsychological tests (5 domains, 2 each). Spearman correlation tests assessed the relationship between cognitive composite and UPSA scores at both baseline and follow-up. 
Eleven participants progressed to a more impaired cognitive classification (3 PD-NC to MCI, 5 PD-MCI to PD dementia (PDD), 3 PD-NC to PDD). Four participants reverted from PD-MCI to PD-NC. UPSA and cognitive composite scores correlated at both baseline (ρ=0.44, p<0.01) and follow-up (ρ=0.55, p<0.01). Baseline UPSA and follow-up cognitive composite score were also correlated (ρ=0.36, p=0.01). There was no significant correlation between baseline UPSA and change in cognitive composite score (ρ=0.094, p=0.54).
The relationship between UPSA and neuropsychological scores was maintained at follow-up, suggesting that UPSA is a valid assessment of cognitive function over time in PD. The lack of a significant relationship between baseline UPSA and change in cognitive composite score may be related to the heterogeneity of cognitive trajectories in our cohort or relatively short duration of follow-up. Continued observation of our growing longitudinal cohort will allow for more thorough investigation of the predictive validity of the UPSA.  
Authors/Disclosures
Tara Carlisle, MD, PhD (University of Colorado AMC Neurology Dept)
PRESENTER 		The institution of Dr. Carlisle has received research support from University of Colorado Denver | Anschutz Medical Campus - NIH Gap Funding. The institution of Dr. Carlisle has received research support from Interdepartmental Alzheimer's Disease Clinical Care and Research Award | Maria Teresa Jones Alzheimer's Disease Fund. The institution of Dr. Carlisle has received research support from NIH/NIA R01AG071151 (PI: Potter). The institution of Dr. Carlisle has received research support from Anschutz Acceleration Initiative Research Grant (PI: Matlock/Glasgow). Dr. Carlisle has received personal compensation in the range of $500-$4,999 for serving as a Speaker with ADRD Research Â鶹´«Ã½Ó³»­ and Appreciation Event. Dr. Carlisle has a non-compensated relationship as a Invited Speaker with Parkinson Association of the Rockies that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Invited Speaker with Women in Neurology Group that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Invited Speaker with Â鶹´«Ã½Ó³»­ that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Invited Speaker with American Neuropsychiatry Association that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Ad hoc Reviewer with The Journal of Neuropsychiatry and Clinical Neurosciences that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Ad hoc Reviewer with Frontiers in Neuroscience, Neurodegeneration Section that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Speaker with Alzheimer's Association that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Expert for Media Reports with UCHealth Today that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Expert for Media Reports with Rocky Mountain PBS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Carlisle has a non-compensated relationship as a Expert for Media Reports with Neurology Today that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
Luis D. Medina, PhD (University of Houston) The institution of Dr. Medina has received research support from National Institutes of Health. Dr. Medina has received personal compensation in the range of $500-$4,999 for serving as a Speaker with AbbVie. Dr. Medina has a non-compensated relationship as a Council Member with Alzheimer's Association that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Samantha K. Holden, MD, MS, FÂ鶹´«Ã½Ó³»­ (University of Colorado School of Medicine) The institution of Dr. Holden has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics.